Syn2bio (WAR:S2B) Other Current Liabilities: zł0.18 Mil (As of Sep. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

WAR:S2B Syn2bio SA WAR:S2B
9 GF Score
Price zł64.00
! 1 Warning Sign
View Full Analysis

What is Syn2bio Other Current Liabilities?

Syn2bio WAR:S2B -0.44% 9 Other Current Liabilities is zł0.18 Mil as of Sep. 2025. GuruFocus rates WAR:S2B with a GF Score™ of 9/100. The stock has 1 warning sign investors should review.

Syn2bio's other current liabilities for the quarter that ended in Sep. 2025 was zł0.18 Mil.

Syn2bio's quarterly other current liabilities increased from Sep. 2023 (zł0.10 Mil) to Sep. 2024 (zł0.12 Mil) and increased from Sep. 2024 (zł0.12 Mil) to Sep. 2025 (zł0.18 Mil).

Syn2bio's annual other current liabilities increased from Sep. 2023 (zł0.10 Mil) to Sep. 2024 (zł0.12 Mil) and increased from Sep. 2024 (zł0.12 Mil) to Sep. 2025 (zł0.18 Mil).

Syn2bio Other Current Liabilities Related Terms

Syn2bio Other Current Liabilities Historical Data

* Premium members only.

The historical data trend for Syn2bio's Other Current Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Syn2bio Other Current Liabilities Chart

Syn2bio Annual Data
Trend Sep23 Sep24 Sep25
Other Current Liabilities
0.10 0.12 0.18

Syn2bio Semi-Annual Data
Sep23 Sep24 Sep25
Other Current Liabilities 0.10 0.12 0.18
WAR:S2B
9GF Score
Syn2bio SA WAR:S2B
Other Current Liabilities is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Syn2bio Other Current Liabilities Calculation

The liability a company needs to pay in the next 12 months, but not assigned to Accounts Payable or Debt. For instance, Wal-Mart (WMT) has accrued wages, salaries, valuation, bonuses, insurance liabilities, accrued tax etc. These are all included in other current liabilities.

What does a Other Current Liabilities of zł0.18 Mil mean?
Syn2bio (WAR:S2B) has a Other Current Liabilities of zł0.18 Mil as of Sep. 2025. Other current liabilities as record on a company's balance sheet not categorized as standard liabilities. View historical data on Syn2bio.
Is Syn2bio's Other Current Liabilities too high?
Syn2bio's current Other Current Liabilities is zł0.18 Mil. Overall, Syn2bio has a GF Score™ of 9/100, reflecting its overall financial health beyond just this single metric.
How does Syn2bio's Other Current Liabilities compare to VRTX and REGN?
Syn2bio's Other Current Liabilities of zł0.18 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Other Current Liabilities for a Biotechnology company?
A good Other Current Liabilities depends on the Biotechnology industry context. However, Other Current Liabilities should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Other Current Liabilities mean?
A high Other Current Liabilities can signal that a stock is expensive relative to its fundamentals. Other current liabilities as record on a company's balance sheet not categorized as standard liabilities. View historical data on Syn2bio. Syn2bio's current Other Current Liabilities is zł0.18 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Syn2bio stock overvalued right now?
Syn2bio (WAR:S2B) has a current Other Current Liabilities of zł0.18 Mil. The current Other Current Liabilities is zł0.18 Mil. Syn2bio's overall GF Score™ is 9/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Other Current Liabilities calculated?
Other Current Liabilities is calculated from a company's financial statements. For Syn2bio (WAR:S2B), the current Other Current Liabilities is zł0.18 Mil as of Sep. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Syn2bio Business Description

Address ul. Jozefa Piusa Dziekonskiego 3, Warszawa, POL, 00-728
Syn2bio SA is a Polish biotech company that develops radiopharmaceuticals. It specializes in developing a cardiac biomarker for diagnosing heart conditions like coronary artery disease through myocardial perfusion imaging. The company's flagship product is the SYN2 cardiotracer. It is applied in the detection of perfusion disorders, evaluation of patients after myocardial infarction or with ischemic heart disease, and assessment of atherosclerotic changes in coronary arteries.
9GF Score

Get the complete analysis for WAR:S2B

Other Current Liabilities is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

zł64.00
Price